Related Experiment Video
Updated: Jun 12, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Cost-effectiveness of lenalidomide in multiple myeloma
1Kings College London School of Medicine, London, SE5 9RS, UK. sschey@kch.nhs.net
Expert Review of Pharmacoeconomics & Outcomes Research
|June 16, 2010
Summary
Lenalidomide, a novel IMiD agent, shows high activity in relapsed/refractory myeloma, improving survival. Understanding health economic models is crucial for patient access to costly novel cancer therapies.
Area of Science:
- Oncology
- Pharmacoeconomics
Background:
- Lenalidomide is a novel immunomodulatory drug (IMiD) with direct and indirect antimyeloma activity.
- It demonstrates significant efficacy in relapsed/refractory multiple myeloma, improving patient survival.
- The high cost of novel agents like lenalidomide attracts scrutiny from regulatory bodies regarding cost-effectiveness.
Purpose of the Study:
- To outline health economic models used by regulatory bodies for novel cancer drug assessments.
- To assess the potential shortcomings of current cost-effectiveness evaluation instruments.
- To suggest alternative methods for evaluating novel agents and identify research gaps.
Main Methods:
- Review of health economic models and cost-effectiveness analysis frameworks.
- Critical assessment of existing instruments used by bodies like NICE.
- Exploration of alternative methodologies for drug appraisal.
Main Results:
- Novel agents like lenalidomide offer improved survival but pose cost challenges.
- Current economic models may not fully capture the value of novel therapies.
- Shortcomings in cost-effectiveness assessments can hinder patient access.
Conclusions:
- Understanding health economic evaluation is vital for ensuring patient access to effective novel cancer treatments.
- There is a need for improved models that accurately reflect the value and cost-effectiveness of innovative therapies.
- Further research is required to refine these evaluation methods.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...